Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home Item
Mechanics of Convective Cell Motion , homeJan. 10, 2025, 11:00 a.m. | Michael Murrell, Ph.D., Associate Professor, Department of Biomedical Engineering and Physics, Yale University | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke
-
Home Item
The Role of Pericytes in Pulmonary Vascular Diseases , homeJan. 17, 2025, 11:00 a.m. | Vinicio de Jesus Perez, M.D., FCCP, FAHA, Assistant Professor, Wall Center Adult PH Clinic Division of Pulmonary and Critical Care Medicine, Stanford School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
Neural Circuits for Social Behaviors , homeJan. 24, 2025, 11:00 a.m. | Marcelo de Oliveira Dietrich, M.D., Ph.D., Associate Professor, Department of Comparative Medicine and Neuroscience, Yale School of Medicine | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home Item
The Role of Exercise-Induced Blood Factor in Partial Reversal of Age-Related Loss of Plasticity in the Brain , homeJan. 31, 2025, 11:00 a.m. | Saul Villeda, Ph.D., Associate Professor, Chair, Department of Biomedical Science, University of California, San Francisco | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home Item
Psychosocial Adjustment to Disability and Disability Identity Development , homeFeb. 14, 2025, 11:00 a.m. | Anjali Forber-Pratt, Ph.D., Director of Research, American Association on Health and Disability | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
How Big Med Drives Rising Healthcare Costs and What to Do About It , homeFeb. 20, 2025, 5:30 p.m. (Reception at 5 p.m.) | Vivian Ho, Ph.D., James A. Baker III Institute Chair in Health Economics, Baker Institute for Public Policy, Rice University | Maury Strauss Distinguished Public Lecture